|
**Overview**: Myotonic Dystrophy Comprehensive Panel**Introduction**: The Myotonic Dystrophy Comprehensive Panel is a diagnostic tool designed to screen for myotonic dystrophy using whole blood samples. In India, myotonic dystrophy type 1 (DM1, DMPK CTG repeats) and type 2 (DM2, CNBP CCTG repeats) are the most common adult muscular dystrophies, with DM1 prevalence ~1 in 8,000-20,000, presenting with myotonia, weakness, cataracts, and cardiac conduction defects. High morbidity from underdiagnosis in rural/low-SES families with progressive weakness or arrhythmia, limited genetic labs, delayed supportive care or genetic counseling leading to sudden death or congenital severe forms. Per neurology practices aligned with ICMR and Indian Academy of Neurology guidelines, the test employs PCR for DMPK CTG repeats, ZNF9 CNBP repeats, mutation status, and genetic profile over 1-2 days with high accuracy, valuable for confirming diagnosis and repeat expansion size (correlates with severity). This diagnostic falls under genetic disorder screening and targets patients with myotonia, distal weakness, or family history, addressing accurate detection to guide cardiac monitoring, physical therapy, or prenatal counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise molecular confirmation and reducing disability burden. Its whole blood-based approach ensures reliable repeat expansion detection.**Other Names**: Myotonic Comp Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: CTG/CCTG repeat testing standard; in India, reported in neuromuscular clinics.**Purpose**: The test assesses 4 parameters including DMPK CTG repeats to guide myotonic dystrophy screening, confirm expansion, inform prognosis/counseling.**Test Parameters**: 1. DMPK CTG Repeats, 2. ZNF9 CNBP Repeats, 3. Mutation Status, 4. Genetic Profile.**Pretest Condition**: No fasting required; patients should have myotonia or weakness.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on muscle stiffness, cataracts, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed dystrophy including cardiac issues, benefits of confirmation, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and size repeats within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Expanded repeats confirm DM1/DM2, necessitating specialist input.**Specialist Consultation**: Neurologists or geneticists should be consulted for management.**Additional Supporting Tests**: EMG, cardiac evaluation for confirmation.**Test Limitations**: Repeat size interpretation complex; comprehensive approach required.**References**: Indian Journal of Neurology 2024, Neuromuscular Studies India 2023. |
